Navigation Links
Keryx Biopharmaceuticals, Inc. Announces First Quarter 2008 Financial Results
Date:5/9/2008

is currently in Phase 2 clinical development for the treatment of hyperphosphatemia (elevated phosphate levels) in patients with end-stage renal disease. The Company is also developing KRX-0401 (perifosine), a novel, potentially first-in-class, oral anti-cancer agent that modulates Akt, a protein in the body associated with tumor survival and growth. KRX-0401 also modulates a number of other key signal transduction pathways, including the JNK and MAPK pathways, which are pathways associated with programmed cell death, cell growth, cell differentiation and cell survival. KRX-0401 is currently in Phase 2 clinical development for multiple tumor types. The Company also has an in-licensing and acquisition program designed to identify and acquire additional drug candidates. Keryx is headquartered in New York City.

Cautionary Statement

Some of the statements included in this press release may be forward- looking statements that involve a number of risks and uncertainties. For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Among the factors that could cause our actual results to differ materially are the following: There can be no assurance that the Company will complete cost- effective clinical trials or meet, as anticipated, the development timelines for the drug candidates in its pipeline, including Zerenex and KRX-0401, or that the Company's stock will not be affected by other risk factors identified from time to time in our reports filed with the Securities and Exchange Commission. Any forward-looking statements set forth in this press release speak only as of the date of this press release. We do not intend to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. This press release and prior releases are available at http://www.keryx.com'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Keryx Biopharmaceuticals to Present at Bank of America Investment Conference
2. Keryx Biopharmaceuticals, Inc. Announces Appointment of Michael P. Tarnok to Board of Directors
3. Keryx Biopharmaceuticals, Inc. Announces Conference Call to Discuss Strategic Alliance
4. Keryx Biopharmaceuticals, Inc. Enters into Licensing Agreement with Japan Tobacco and Torii Pharmaceutical for Development and Commercialization of Hyperphosphatemia Drug in Japan
5. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Third Quarter 2007 Financial Results on Thursday, October 25, at 8:30 A.M. EDT
6. Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2007 Financial Results
7. Keryx Biopharmaceuticals Announces Upcoming Corporate Presentations
8. Keryx Biopharmaceuticals Announces Additions to Management Team
9. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Fourth Quarter and Year-End 2007 Financial Results on Monday, February 25, at 8:30 A.M. EST
10. Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2007 Financial Results
11. Keryx Biopharmaceuticals Announces that SUN-MICRO Phase 3 Clinical Trial Fails to Meet Primary Efficacy Endpoint
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... licensed to biotechnology firms has revealed early bottlenecks ... roadblocks, the researchers suggest that better communication of ... lead to faster commercialization down the road. , ... in university laboratories and licensed to biotechnology firms. ... have a high failure rate. But a new ...
(Date:8/20/2014)... have succeeded in measuring vibrational motion of a single ... how vibration of a single molecule differs from the ... was performed at the University of California, Irvine, where ... works as a visiting fellow under professor Vartkess A. ... team was lead by Professor Eric O. Potma. The ...
(Date:8/20/2014)... August 20, 2014 High performance ... apply the most complete climate and Earth system ... climate change issues. , Eight national laboratories, including ... the National Center for Atmospheric Research, four academic ... effort. Other participating national laboratories include Argonne, Brookhaven, ...
(Date:8/20/2014)... Aug. 20, 2014  PAREXEL International Corporation (NASDAQ: ... presenting at the Baird Healthcare Conference in New York.  ... Financial Officer, will be making a presentation on PAREXEL ... Wednesday, Sept. 3, 2014. A live webcast ... section of PAREXEL,s website at www.PAREXEL.com in ...
Breaking Biology Technology:Early bottlenecks in developing biopharmaceutical products delay commercialization 2Early bottlenecks in developing biopharmaceutical products delay commercialization 3Seeing a molecule breathe 2New Project Is the ACME of Addressing Climate Change 2New Project Is the ACME of Addressing Climate Change 3PAREXEL International To Present At Baird Healthcare Conference 2
... (Amex: IMM ) will have an investor conference ... to discuss its financial results for the quarter,ended December ... Company,s,scientific and clinical progress. Investors and interested parties in ... (888) 338-8374 and callers,outside the U.S. should call (706) ...
... 6 Mediware Information,Systems, Inc. (Nasdaq: MEDW ) ... repurchase of up to $4 million of the company,s ... and Chief Executive Officer or Chief,Financial Officer of the ... obligation to repurchase shares under the program., Commenting, ...
... ... Services Network, POWAY, Calif., Feb. 6 ... diagnostic imaging systems,and services to physicians, offices, hospitals and imaging centers, ... American,Nuclear Medicine Equipment Product Line Strategy Award., Travis Chong, research ...
Cached Biology Technology:Immtech Investor Conference Call Scheduled for February 11, 2008 2Mediware Board Authorizes $4 Million Stock Buyback 2Digirad Corporation to Receive Frost & Sullivan 2007 North American Award for Product Strategy 2Digirad Corporation to Receive Frost & Sullivan 2007 North American Award for Product Strategy 3
(Date:8/21/2014)... -- Nxt-ID, Inc. (OTCQB: NXTD), a biometric authentication company ... that its shares of common stock and the warrants ... proposed underwritten public offering of common stock and warrants ... Market, subject to closing of its proposed underwritten public ... trade under the symbol "NXTD" and "NXTDW," respectively. ...
(Date:8/21/2014)... fungus linked to dandruff, eczema and other itchy, flaky ... further global reachesincluding Hawaiian coral reefs and the extreme ... A review in the scientific journal PLOS Pathogens ... fungi of the genus Malassezia in light ... from around the world. , University of Hawai,i at ...
(Date:8/21/2014)... Beth Israel Deaconess Medical Center (BIDMC ) are among ... Scientific Minds 2014," a comprehensive list compiled ... for science metrics and research performance analysis. ... "are performing and publishing work that their peers recognized ... to a Thomson Reuters statement. Researchers were identified based ...
Breaking Biology News(10 mins):Nxt-ID Approved for NASDAQ Capital Market Listing 2Nxt-ID Approved for NASDAQ Capital Market Listing 3From dandruff to deep sea vents, an ecologically hyper-diverse fungus 2BIDMC researchers named among 'the most influential scientific minds' 2BIDMC researchers named among 'the most influential scientific minds' 3
... Are members of the public divided about climate ... If Americans knew more basic science and were more ... consensus? A study published today online in the ... answer to both questions is no. Indeed, as members ...
... common house sparrow and a Tyrannosaurus Rex might have anything in ... an ounce, and the other is a dinosaur that was the ... than eight tons. For all their differences, though, scientists ... A new study, led by Harvard scientists, has shown that modern ...
... El Nio was associated with higher mortality for eggs and ... could be worsened by continuing global climate change, according to ... PLoS ONE . The El Nio Southern Oscillation brought ... major nesting sites in the area. The researchers, led by ...
Cached Biology News:Yale study concludes public apathy over climate change unrelated to science literacy 2Timing is everything 2Timing is everything 3Timing is everything 4
CleanCut agarose is used to prepare genomic DNA plugs for use in pulsed field gel electrophoresis (PFGE) applications. Supplied as a 12 ml solution of 2% agarose....
... fluorescent minor groove-binding probe for DNA. Binds ... (preferentially to AT rich DNA), forming a ... greater than DAPI alone. DAPI is several ... staining DNA in agarose gels. It may ...
...
... FailSafe™ PCR System is the only PCR ... time and every time. It provides accuracy, ... the source or the property of the ... PCR Enzyme Mix, a unique blend of ...
Biology Products: